XFOR vs. LFVN, SOPH, VYGR, RZLT, TNGX, MNPR, MDWD, ALMS, INMB, and TVGN
Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include LifeVantage (LFVN), SOPHiA GENETICS (SOPH), Voyager Therapeutics (VYGR), Rezolute (RZLT), Tango Therapeutics (TNGX), Monopar Therapeutics (MNPR), MediWound (MDWD), Alumis (ALMS), INmune Bio (INMB), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry.
X4 Pharmaceuticals vs.
LifeVantage (NASDAQ:LFVN) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability.
35.3% of LifeVantage shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 20.7% of LifeVantage shares are owned by insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
LifeVantage has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
LifeVantage has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
LifeVantage has a net margin of 3.46% compared to X4 Pharmaceuticals' net margin of 0.00%. LifeVantage's return on equity of 34.29% beat X4 Pharmaceuticals' return on equity.
LifeVantage currently has a consensus target price of $30.50, suggesting a potential upside of 102.93%. X4 Pharmaceuticals has a consensus target price of $2.83, suggesting a potential upside of 945.12%. Given X4 Pharmaceuticals' higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than LifeVantage.
LifeVantage received 144 more outperform votes than X4 Pharmaceuticals when rated by MarketBeat users. Likewise, 77.97% of users gave LifeVantage an outperform vote while only 68.10% of users gave X4 Pharmaceuticals an outperform vote.
In the previous week, X4 Pharmaceuticals had 10 more articles in the media than LifeVantage. MarketBeat recorded 12 mentions for X4 Pharmaceuticals and 2 mentions for LifeVantage. LifeVantage's average media sentiment score of 1.71 beat X4 Pharmaceuticals' score of 0.20 indicating that LifeVantage is being referred to more favorably in the media.
Summary
LifeVantage beats X4 Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get X4 Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
X4 Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:XFOR) was last updated on 3/27/2025 by MarketBeat.com Staff
Buy XFOR Stock Free XFOR Stock Alerts